

GLAXOSMITHKLINE PLC  
Form 6-K  
March 18, 2013

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington D.C. 20549

**FORM 6-K**

**Report of Foreign Issuer**

**Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934**

March 18, 2013

**GlaxoSmithKline plc**

**GlaxoSmithKline Capital plc**  
(Name of registrant)

**GlaxoSmithKline Capital Inc.**  
(Name of registrant)

980 Great West Road, Brentford,

1105 North Market Street, Suite 622,

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

**Middlesex, TW8 9GS**  
(Address of principal executive offices)

**Wilmington, Delaware 19801**  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F       Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes       No

THIS REPORT ON FORM 6-K SHALL BE DEEMED TO BE INCORPORATED BY REFERENCE IN THE PROSPECTUS INCLUDED IN THE REGISTRATION STATEMENT ON FORM F-3 (FILE NO. 333-172621) OF GLAXOSMITHKLINE PLC, GLAXOSMITHKLINE CAPITAL PLC AND GLAXOSMITHKLINE CAPITAL INC. AND TO BE A PART THEREOF FROM THE DATE ON WHICH THIS REPORT IS FURNISHED, TO THE EXTENT NOT SUPERSEDED BY DOCUMENTS OR REPORTS SUBSEQUENTLY FILED OR FURNISHED.

## Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

---

GlaxoSmithKline plc, GlaxoSmithKline Capital plc and GlaxoSmithKline Capital Inc. hereby incorporate by reference the following exhibits to this report on Form 6-K into their Registration Statement on Form F-3 (File Nos. 333-172621, 333-172621-01, 333-172621-02).

| Exhibit No. | Description of Document  |
|-------------|--|
| 1.1         | Underwriting Agreement, dated as of March 13, 2013, among GlaxoSmithKline Capital Inc., GlaxoSmithKline plc, Deutsche Bank Securities Inc., Goldman, Sachs & Co., J.P. Morgan Securities LLC and UBS Securities LLC, as representatives of the several underwriters named therein. |
| 4.1         | First Supplemental Indenture, dated as of March 18, 2013, among GlaxoSmithKline Capital Inc., GlaxoSmithKline plc and Law Debenture Trust Company of New York.   |
| 5.1         | Opinion of Cleary Gottlieb Steen & Hamilton LLP, special U.S. counsel to GlaxoSmithKline plc and GlaxoSmithKline Capital Inc.  |
| 5.2         | Opinion of Cleary Gottlieb Steen & Hamilton LLP, special English counsel to GlaxoSmithKline plc and GlaxoSmithKline Capital Inc.   |

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrants have duly caused this report to be signed on their behalf by the undersigned, thereunto duly authorised.

**GlaxoSmithKline plc**  
**GlaxoSmithKline Capital plc and**  
**GlaxoSmithKline Capital Inc.**  
(Registrants)

Date: March 18, 2013

By: /s/ Victoria Whyte

Victoria Whyte  
Authorised Signatory for and on behalf of  
GlaxoSmithKline plc  
GlaxoSmithKline Capital plc and  
GlaxoSmithKline Capital Inc.